99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients

Overview

This is an open-label single photon emission computed tomography / computed tomography (SPECT/CT) study to investigate the safety and diagnostic performance of 99mTc-HYNIC-3PEG4-E[c(RGDfK)2) (99mTc-3PRGD2) in esophagus cancer patients. A single dose of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 ( ≤ 20 µg 3PRGD2) will be intravenously injected into the patients in suspicion of esophagus cancer. Visual and semiquantitative method will be used to assess the whole-body planar and thoracic SPECT/CT images. Any adverse events will be collected from the patients.

Full Title of Study: “Safety and Diagnostic Performance of 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2017

Detailed Description

Integrin αvβ3 is an important member of integrin receptor family and expressed preferentially on the activated endothelial cells of angiogenesis and some types of tumor cells, but not or very low on the quiescent vessel cells and other normal cells. Therefore, the integrin αvβ3 receptor is becoming a valuable target for diagnosis and response evaluation of malignant tumors. The tri-peptide sequence of arginine-glycine-aspartic acid (RGD) can specifically bind to the integrin αvβ3 receptor. Accordingly, a variety of radiolabeled RGD-based peptides have been developed for non-invasive imaging of integrin αvβ3 expression via single photon emission computed tomography (SPECT)or positron emission tomography (PET). Among all the RGD radiotracers studied, several RGD monomers have been investigated in clinical trials, and the preliminary results demonstrated specific imaging of various types of tumors, and the tumor uptake correlated well with the level of integrin αvβ3 expression. Recently, several RGD dimeric peptides with PEG linkers have been studied. The new types of RGD peptides showed much higher in vitro integrin αvβ3-binding affinity than the single RGD tri-peptide sequence, and importantly, they exhibited significantly increased tumor uptake and improved in vivo kinetics in animal models. As a representative, 99mTc-3PRGD2 could be easily prepared and exhibited excellent in vivo behaviors in animal models. No adverse reactions are observed in animal models to date. For the further interests in clinical translation of 99mTc-3PRGD2, an open-label SPECT/CT study was designed to investigate the safety and diagnostic performance of 99mTc-3PRGD2 in esophagus cancer patients. A single dose of nearly 11.1 MBq/kg body weight 99mTc-3PRGD2 ( ≤ 20 µg 3PRGD2) will be intravenously injected into the esophagus cancer patients. Visual and semiquantitative method will be used to assess the whole-body planar and thoracic SPECT/CT images. Adverse events will also be observed in the patients.

Interventions

  • Drug: 99mTc-3PRGD2
    • For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.

Arms, Groups and Cohorts

  • Experimental: Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT
    • Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.

Clinical Trial Outcome Measures

Primary Measures

  • Visual Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan
    • Time Frame: one year
    • Visual analysis will be performed by 3 experienced nuclear medicine physicians to observe the the uptake of 99mTc-3PRGD2 on esophagus lesions. The visual analysis interpreter’s degree of suspicion for an abnormality was recorded with use of a 3-point with the following categories: score 1, no abnormal increased uptake; score 2, mildly increased uptake; score 3, definite focal increased uptake. The lesion was considered positive as malignancy if the lesion scored as 2 or higher.
  • Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan
    • Time Frame: one year
    • The semiquantitative analysis of the standardized uptake values (SUV) of 99mTc-3PRGD2 SPECT/CT was performed on esophagus lesion

Secondary Measures

  • 18F-FDG PET/CT Scan
    • Time Frame: one year
    • 18F-FDG PET/CT will be carried out in esophagus cancer patients to assess the uptake of esophagus lesions or distant metastasis and the standardized uptake values (SUVs) of these lesions will be measured.
  • Laboratory Values
    • Time Frame: one year
    • The blood level of CEA(carcino-embryonic antigen,ng/ml)in participants will be recorded.
  • Adverse events collection
    • Time Frame: 5 days
    • Adverse events within 5 days after the injection and scanning of the patients will be followed and assessed. The number of participants with adverse events and abnormal laboratory values will be recorded.
  • Contrast-enhanced CT
    • Time Frame: one year
    • Contrast-enhanced CT will be carried out in esophagus cancer patients to observe the location and tumor diameter (cm).

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females, ≥30 years old – Thoracic CT and/or gastroscopy diagnosis in suspicion of primary or recurrent lung cancer. – The lung cancer will be histologically confirmed or results of histology will be available. Exclusion Criteria:

  • Females planning to bear a child recently or with childbearing potential – Known severe allergy or hypersensitivity to IV radiographic contrast. – Inability to lie still for the entire imaging time because of cough, pain, etc. – Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. – Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the Investigator, may significantly interfere with study compliance.

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • First Affiliated Hospital of Fujian Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Weibing Miao, PhD, PhD – First Affiliated Hospital of Fujian Medical University
  • Overall Official(s)
    • Weibing Miao, MD, Study Director, First Affiliated Hospital of Fujian Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.